Research Topics
| Arthur L WeaverSummaryAffiliation: University of Nebraska Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Current and emerging treatments for mild/moderate acute ambulatory painArthur L Weaver
Section of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, USA
Am J Ther 15:S12-6. 2008..Topical NSAIDs and other formulations that may prove to be safer than currently available agents also are addressed...
Epidemiology of goutArthur L Weaver
Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, USA
Cleve Clin J Med 75:S9-12. 2008..While dietary and lifestyle modification may be useful as adjunctive measures, such changes do not replace pharmacologic treatments for gout or associated comorbidities...
Case 3: acute gout-risk factors and inappropriate therapyArthur L Weaver
Division of Rheumatology, University of Nebraska Medical Center, Omaha, Nebraska, USA
Am J Med 119:S9-12. 2006
Case 1: differential diagnosis of an acute gouty attackArthur L Weaver
Division of Rheumatology, University of Nebraska Medical Center, Omaha, Nebraska, USA
Am J Med 119:S2-3. 2006
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registryArthur L Weaver
University of Nebraska Medical Center, Omaha, NE, USA
Curr Med Res Opin 22:185-98. 2006..To evaluate the effectiveness of select biologics, methotrexate (MTX), and other disease-modifying anti-rheumatic drugs (DMARDs) in the management of adult rheumatoid arthritis (RA) in routine clinical practice...
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetoneArthur L Weaver
University of Nebraska Medical Center, Omaha, Nebraska, USA
J Clin Rheumatol 12:17-25. 2006..Rofecoxib and nabumetone were developed to provide gastrointestinal benefits over traditional nonsteroidal antiinflammatory drugs (NSAIDs). However, there is limited comparative information relating to these 2 drugs...
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. 1989Grant W Cannon
Division of Rheumatology, University of Utah, Salt Lake City, UT 84132, USA
Arthritis Rheum 58:S79-88. 2008..Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant...
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled studyDesiree van der Heijde
Department of Internal Medicine, Division of Rheumatology, University Hospital, Maastricht, The Netherlands
Arthritis Rheum 52:1205-15. 2005..To assess the efficacy, safety, and tolerability of etoricoxib, a cyclooxygenase 2 (COX-2) selective inhibitor, administered continuously over 52 weeks for the treatment of ankylosing spondylitis (AS)...
Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritisTed R Mikuls
Section of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha Veterans Administration Medical Center, 983025 Nebraska Medical Center, Omaha, NE 68198, USA
Curr Rheumatol Rep 5:270-7. 2003..This review evaluates the unique attributes of the available TNFa inhibitors, focusing specifically on recent reports providing important insight into the understanding of drug-related efficacy and toxicity...
Current state of therapy for pain and inflammationSteven B Abramson
New York University School of Medicine, New York, USA
Arthritis Res Ther 7:S1-6. 2005....
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritisJohn D Bradley
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
J Rheumatol 32:417-23. 2005..To evaluate the efficacy and safety of a selective inhibitor of secretory phospholipase (sPLA2), LY333013, in the treatment of rheumatoid arthritis (RA)...
Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trialsWendy P Battisti
Merck and Co, Inc, West Point, Pennsylvania 19486, USA
J Pain 5:511-20. 2004..Rofecoxib provides significantly faster time to onset of efficacy and better improvement on multiple measures versus the comparators...
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial resultsRoy M Fleischmann
University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
J Rheumatol 30:691-6. 2003..CONCLUSION: Etanercept is a new treatment option for older patients with RA and has substantial benefit and comparable safety regardless of patient age...
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugsArthur L Weaver
Arch Intern Med 162:2248-9. 2002
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesMark C Genovese
Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road 203, Palo Alto, CA 94304, USA
Arthritis Rheum 46:1443-50. 2002..To compare the clinical and radiographic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy...
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trialGregory P Geba
Merck and Co Inc, US Human Health, PO Box 4, West Point, PA 19486 0004, USA
JAMA 287:64-71. 2002..Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2)...
